BioSpace News Archive

Emergex Vaccines Holding Limited (‘Emergex’) today announced positive outcomes from its first-in-human clinical trial of DengueTcP (trademark application submitted), a candidate against Dengue virus, the causative agent for Dengue Fever.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that it has entered into definitive agreements for the purchase and sale of 9,670,002 shares of common stock at a purchase price of $0.65 per share of common stock in a registered direct offering.

The most recent developments from Octapharma’s Haematology and Critical Care portfolios will be presented at the 31st Congress of the International Society on Thrombosis and Haemostasis on June 24–28, 2023, in Montréal, Canada.

Britannia Life Sciences Inc. (CSE: BLAB) (FSE: L020) (“Britannia”) is excited to announce the acquisition of an initial 51% interest in Cosmetics Lab Ltd. (“CosLab”).

Replimune Group, Inc. announced initial data from ARTACUS, a Phase 1/2 trial evaluating RP1 for the treatment of cutaneous malignancies in patients who have had a kidney, liver, heart, lung, and/or a hematopoietic cell transplant.

From June 5th to 8th (Pacific Standard Time), the 2023 BIO International Convention (“BIO 2023") will be held in Boston, Massachusetts , USA.

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with William Pao, Chief Development Officer, Executive Vice President, at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13, 2023 at 8:00 a.m. Pacific Daylight Time.

Today, the U.S. Food and Drug Administration is announcing the availability of a draft guidance with updated recommendations for good clinical practices (GCPs) aimed at modernizing the design and conduct of clinical trials, making them more agile without compromising data integrity or participant protections.

Olympus Corporation, a global medical technology company committed to making people’s lives healthier, safer and more fulfilling, announced market availability of its newest electrosurgical generator for use in the treatment of bladder cancer and enlarged prostate.

Harnessing and boosting a patient’s own immune system to help fight cancer through immunotherapies like monoclonal antibodies and engineered T cells has become a standard of care for some cancers over the past two decades.